Which generation of EGFR targeted inhibitor drugs does Lazertinib belong to?

Lazertinib (Lazertinib) is a third-generation EGFR (epidermal growth factor receptor) targeted inhibitor drug, specially designed to treat patients with Patients with non-small cell lung cancer (NSCLC) with EGFRsensitive mutations and T790Mresistant mutations. As a third-generation EGFR inhibitor, lanzitinib has higher selectivity and stronger inhibitory ability, and can effectively overcome the resistance problem caused by the T790M mutation of previous-generation drugs.

Compared with the first and second generation EGFR inhibitors, Lanzertinib can not only target the common 19 exon deletion and 21 exon The span>L858R mutation can also selectively inhibit the T790M mutation, reduce the inhibition of wild-type EGFR, and reduce the incidence of side effects, such as rash and diarrhea. Clinical studies have shown that lanzatinib has a significant objective response rate and prolonged progression-free survival in patients with T790M-positive NSCLC, and it also has good efficacy in central nervous system metastasis.

The research and development background of Lanzertinib mainly stems from in-depth research on the mechanism of drug resistance. First-generation EGFR inhibitors such as gefitinib and icotinib are effective for a period of time, but most patients lose efficacy due to the T790M resistance mutation. Although second-generation drugs such as afatinib can inhibit some drug-resistant mutations, they have greater toxic and side effects. The third-generation drug Lanzetinib addresses this problem, maintaining strong anti-cancer activity while significantly reducing toxic and side effects, improving patients' quality of life.

In short, lanzatinib, as a third-generation EGFR targeted inhibitor, is an important drug option for the current treatment of EGFR mutation-positive non-small cell lung cancer. With its ability to precisely target T790M resistance mutations, it provides patients with new treatment options, especially in overcoming drug resistance and central nervous system metastasis. In the future, with the accumulation of more clinical data, lanzitinib is expected to help more lung cancer patients improve their prognosis worldwide.

Reference materials:https://www.drugs.com